A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis

Journal of Drugs in Dermatology

Volumn 11, Issue 3, 2012, Pages 341-346

  Volf, Eva M ^a   Au, Shiu Chung ^b   Dumont, Nicole ^b   Scheinman, Pamela ^b   Gottlieb, Alice B ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; APREMILAST; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; RANTES;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA ASSESSMENT SEVERITY INDEX; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; INVESTIGATOR GLOBAL ASSESSMENT SCORE; LOOSE FECES; MALE; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRURITUS; QUALITY OF LIFE INDEX; SHORT FORM 36; SIDE EFFECT; SINUS ARRHYTHMIA; SKIN ALLERGY; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858636270     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Thyssen JP, Linneberg A, Menné T, Johansen JD. The epidemiology of contact allergy in the general population-prevalence and main findings. Contact Dermatitis. 2007;57(5):287-299. (Pubitemid 47568789)
2. Akhavan A, Cohen SR. The relationship between atopic dermatitis and contact dermatitis. Clin Dermatol. 2003;21(2):158-162. (Pubitemid 36428986)
3. Zug KA, Warshaw EM, Fowler JF Jr., et al. Patch-test results of the North America Contact Dermatitis Group 2005-2006. Dermatitis. 2009;20(3):149-160.
4. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842-855.
5. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24(5):1529-1538. (Pubitemid 351741586)
6. Positive phase IIb topline clinical data for Celgene oral compound apremilast (cc-10004) reported for patients with moderate-to-severe psoriasis. Press Release: Dec, 15, 2009. Summit, NJ: Celgene Corporation.
7. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107(1):51-56. (Pubitemid 26236094)
8. Teixeira MM, Rossi AG, Williams TJ, Hellewell PG. Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br J Pharmacol. 1994;112(1):332-340. (Pubitemid 24151748)
9. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-1494.
10. Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing "T22" T cells account for upgraded IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009;123(6):1244-1252.
11. Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy. 2009;64(12):1699-1714.
12. Larsen JM, Bonefeld CM, Poulsen SS, Geisler C, Skov L. IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis. J Allergy Clin Immunol. 2009;123(2):486-492.
13. Aronson PJ, Yeung-Yue KA. Treatment of hand dermatitis with alefacept. Dermatitis. 2008;19(3):161-162.
14. Bremmer MS, Bremmer SF, Baig-Lewis S, Simpson EL. Are biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactions. J Am Acad Dermatol. 2009;61(4):666-676.